Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

258 results about "Enterocyte" patented technology

Enterocytes, or intestinal absorptive cells, are simple columnar epithelial cells which line the inner surface of the small intestine. A glycocalyx surface coat contains digestive enzymes. Microvilli on the apical surface increase its surface area. This facilitates transport of numerous small molecules into the enterocyte from the intestinal lumen. These include broken down proteins, fats, and sugars, as well as water, electrolytes, vitamins, and bile salts. Enterocytes also have a endocrine role, secreting hormones such as leptin.

Metabolite screening method for promoting expression of porcine intestinal defensin pBD1 and application of metabolite screening method

The invention discloses a metabolite screening method for promoting expression of porcine intestinal defensin pBD1 and application of the metabolite screening method. The screening method comprises the following steps: 1) constructing a porcine defensin pBD1 gene fluorescence report intestinal epithelial cell line; 2) evaluating the promotion effects of different metabolites based on the pBD1 gene fluorescence report intestinal epithelial cell line; and 3) further evaluating the promotion effects of the metabolites screened in the step 2) based on a porcine intestinal epithelial cell IPEC-J2 model. And 4) further evaluating the promotion effect of the metabolite screened in the step 3) based on the pig intestinal organ. The invention can be used for preparing or screening drugs influencing the expression of the porcine intestinal defensin pBD1. According to the application disclosed by the invention, the effect of the D-malic acid for improving the immune function of the pig intestinal tract by promoting the expression of the defensin pBD1 is found for the first time, verification is carried out on a pig intestinal tract organ-like model, and meanwhile, the optimal treatment concentration of the D-malic acid for promoting the expression of the defensin pBD1 in the pig intestinal tract is optimized.
Owner:ZHEJIANG UNIV

In vitro model of inflamed intestinal barrier

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Owner:UNIVERSITE DE FRANCHE COMTE

Lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as product and application of lactobacillus rhamnosus

The invention discloses lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as a product and application thereof, and relates to the technical field of microorganisms. The lactobacillus rhamnosus NHNK-604 disclosed by the invention is preserved in the China Center for Type Culture Collection on March 7, 2024, and the preservation number of the lactobacillus rhamnosus NHNK-604 is CCTCC (China Center for Type Culture Collection) NO: M 2024417. The NHNK-604 has the functions of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, reducing inflammation and apoptosis of the vascular endothelial cells, reducing aging damage of cerebral micro-blood endothelial cells and promoting blood-brain barriers. In addition, the thallus biological membrane can increase colonization of mucoprotein and intestinal epithelial cells, and can be used for preparing products for improving thrombus and cerebral apoplexy.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Application of Piezo1 inhibitor in preparation of medicine for treating necrotizing enterocolitis

PendingCN119258220ASubstance reductionimprove survival rateOrganic active ingredientsDigestive systemCalmodulin-dependent protein kinase activityHistiocyte
The invention discloses an application of a Piezo1 inhibitor in preparation of a medicine for treating necrotizing enterocolitis. The Piezo1 inhibitor can be applied in preparation of the medicine for treating the necrotizing enterocolitis. The Piezo1 inhibitor can also be applied to preparation of drugs for relieving NEC intestinal epithelial barrier injury. The Piezo1 inhibitor can also be applied to preparation of drugs for reducing calcium influx in intestinal epithelial cells and calcium / calmodulin dependent protein kinase activity. The application has the beneficial effects that the effect and mechanism of the Piezo1 for regulating and controlling the calcium ion influx and promoting the NEC severity degree by the calcium / calmodulin dependent protein kinase activity level are discussed for the first time from multiple aspects of animals, tissues, cells, molecules and the like, and the effect and mechanism of the activated intestinal epithelial cell Piezo1 in NEC inflammatory injury and barrier repair are clarified for the first time; the knockout of the gene can improve the NEC severity of mice, and a new intervention target is provided for clinical treatment.
Owner:JILIN UNIVERSITY

Exosome composition for resisting neurodegeneration as well as preparation method and application thereof

The invention discloses an anti-neurodegeneration exosome composition as well as a preparation method and application thereof. The anti-neurodegeneration exosome composition is prepared from the following components in parts by mass: 5 to 25 parts of human exfoliated deciduous tooth stem cell exosome, 25 to 85 parts of plant-derived exosome-like nano-vesicles, 12 to 10 parts of ginsenoside Rg, 2 to 10 parts of curcumin and 10 to 20 parts of auxiliary materials. The anti-neurodegeneration exosome composition contains a large amount of cell factors, growth factors, miRNA, mRNAs and other components, is easy to fuse with cell membranes of intestinal epithelial cells, can selectively deliver bioactive substances to recipient cells through a blood-brain barrier, carries out information transmission among different cells, regulates signal transduction among the cells, and has a good anti-neurodegeneration effect. The effects of resisting oxidation, resisting inflammation, resisting aging and the like are achieved.
Owner:襄阳市第一人民医院

Berberine carbon nanodot as well as preparation method and application thereof

The invention discloses berberine carbon nanodots as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: carrying out a hydrothermal reaction on a berberine aqueous solution, filtering, centrifuging and collecting the solution. The berberine is used as a unique carbon source, the high-fluorescence carbon nanodot is synthesized through a hydrothermal method, the method is simple, low in cost, safe and green, other chemical reagents do not need to be added, potential toxicity caused by other chemical substances is avoided, and the berberine carbon nanodot obtained through synthesis is small in size, has good water solubility, can penetrate through a cell membrane and can be used for preparing the high-fluorescence carbon nanodot. The compound provided by the invention is simple in preparation process and easy for intestinal tissue cell uptake, can significantly alleviate intestinal epithelial cell death and intestinal epithelial cell barrier permeability abnormity caused by LPS (lipopolysaccharide) by alleviating intestinal tissue pathological injury, inflammatory response and tight junction protein loss of sepsis mice, and is effectively applied to treatment of intestinal barrier injury caused by sepsis.
Owner:TIANJIN PEOPLE HOSPITAL

Lactobacillus plantarum grx402 having the ability to promote intestinal absorption of short-chain fatty acids

This invention discloses a strain of *Lactobacillus plantarum* Grx402 with the ability to promote intestinal absorption of short-chain fatty acids. *Lactobacillus plantarum* Grx402 was isolated from the intestines of long-lived individuals in Bama, Guangxi (CGMCC No. 28585). Using a Caco-2 cell model to construct an intestinal absorption model of short-chain fatty acids (SCFAs), it was found that *Lactobacillus plantarum* Grx402 can promote the absorption and transport of acetic acid, propionic acid, and butyric acid by intestinal epithelial cells, exhibiting excellent ability to promote intestinal absorption of short-chain fatty acids. It can be used to prepare dairy products or beverages that promote the intestinal absorption of short-chain fatty acids.
Owner:YANGZHOU UNIV

Application of Propionibacterium freudenreichii subsp. Scheri in preparation of products for improving macular retinae

PendingCN120478417ASenses disorderBacteria material medical ingredientsBiotechnologyRetinal neovascularization
The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Bifidobacterium bifidum and application thereof in improving asthma and histamine intolerance

ActiveCN119144528AReduce receptor activationreduce remodelingBacteriaAntinoxious agentsBiotechnologyHistamine intolerance
The invention discloses bifidobacterium bifidum and application thereof in improving asthma and histamine intolerance, and belongs to the technical field of marine microorganisms. The bifidobacterium bifidum NHNK-618 is preserved in the China Center for Type Culture Collection on August 9, 2024, and the preservation number of the bifidobacterium bifidum NHNK-618 is CCTCC (China Center for Type Culture Collection) NO: M20241761. The NHNK-618 has the functions of regulating asthma-related flora, agglutinating asthma-related pathogenic bacteria, reducing staphylococcus aureus enterotoxin, reducing bronchial histamine receptor activation, promoting bronchial barrier integrity, reducing airway remodeling and degrading histamine, and in addition, an NHNK-618 thallus biological membrane can improve the colonization capability on intestinal epithelial cells. The compound can be used for preparing products for improving asthma and histamine intolerance.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Lipid nanoparticle, targeted lipid nanoparticle, preparation method and application

The invention discloses a lipid nanoparticle, a targeted lipid nanoparticle, and a preparation method and application thereof. The lipid nanoparticle has a core-shell structure, the core is formed by PLGA nanoparticles containing drug molecules, and the shell is formed by raw materials including phospholipid, cholesterol and a modification material; wherein the PLGA nanoparticles containing the drug molecules are formed by raw materials comprising PLGA and the drug molecules; the mass ratio of the PLGA to the phospholipid is (1-5): 1; the mass ratio of the phospholipid to the cholesterol is (3-10): 1, and the mass ratio of the phospholipid to the modification material is (3-10): 1; the drug molecules are selected from one or more of insoluble drugs, water-soluble drugs, genes and proteins; and the modification material is PEG-DSPE (Polyethylene Glycol Distearoyl The hardness of the lipid nanoparticles can be regulated and controlled, and cellular uptake can be improved by regulating and controlling the hardness; the targeted lipid nanoparticles can better improve cellular uptake, promote intestinal epithelial cell absorption and improve oral curative effect.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and application of lactobacillus rhamnosus composition

The invention discloses a lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and application of the lactobacillus rhamnosus composition, the composition is composed of a probiotic mixture, a prebiotic mixture and a carrier, the probiotic mixture is composed of lactobacillus plantarum JY055 bacterial powder, lactobacillus rhamnosus JM039 bacterial powder and lactobacillus rhamnosus JY027 bacterial powder, and the prebiotic mixture is composed of lactobacillus plantarum JY055 bacterial powder, lactobacillus rhamnosus JM039 bacterial powder and lactobacillus rhamnosus JY027 bacterial powder. The prebiotic mixture comprises inulin, xylitol, lactulose, resistant dextrin, a hawthorn extract and a dandelion extract, and the carrier is modified montmorillonite. The composition for relieving gastrointestinal diarrhea provided by the invention is composed of a mixture of three probiotics and prebiotics, and the probiotics are adhered to small intestinal mucosa epithelial cells to form a mycoderm and form an intestinal barrier, so that colonization and growth of harmful bacteria are prevented, self-protection of intestinal epithelial cells is enhanced, and the damaged intestinal barrier is repaired; the prebiotic mixture provides a breeding place and nutrient elements for growth and breeding of the probiotics, and the efficacy can be improved through mutual cooperation of the prebiotic mixture and the probiotics.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of coronary heart disease and sclerotin

The invention discloses application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of coronary heart disease and sclerotin, and belongs to the technical field of marine microorganisms. The invention discloses a leuconostoc mesenteroides subsp. Mesenteroides NHNK-613, which is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the leuconostoc mesenteroides subsp. Mesenteroides NHNK-613 is CCTCC (China Center for Type Culture Collection) NO: M 20241431. The NHNK-613 has the capabilities of adsorbing calcium ions, up-regulating intestinal epithelial cell calcium and vitamin D absorption and transfer related gene expression, promoting intestinal absorption and transfer of calcium ions, promoting intestinal tract conversion of 1, 25-dihydroxy vitamin D3, promoting myocardial cell repair, regulating bone metabolism related genes, promoting osteoblast repair and promoting vascular endothelial cell repair. The composition can be used for preparing products for improving coronary heart disease and sclerotin.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Composition for promoting differentiation of intestinal immune cells as well as preparation method and application of composition

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.
Owner:AUSNUTRIA DAIRY CHINA

Application of engineered citrobacter freundii in fermentation synthesis of stabilizers

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.
Owner:NANJING UNIV

An aggregate formed by the assembly of a chalcogen heterocyclic compound and insulin, a preparation method thereof, and an oral insulin preparation

The present invention provides an aggregate, a preparation method thereof, and an oral insulin formulation. Specifically, an aggregate formed by the assembly of a chalcogen heterocyclic compound and insulin is provided. The aggregate can be further prepared into an oral insulin formulation. The oral formulation can be used to lower the blood glucose level of mammals and is used as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the oral insulin formulation prepared by this method can effectively protect insulin from overcoming the three major physiological barriers of the oral intake route, is stable in the gastrointestinal environment, and undergoes a dynamic chemical exchange reaction with the sulfhydryl groups of intestinal mucin in intestinal fluid and the proteins on the inner and outer sides of the epithelial cell membrane through the surface poly-chalcogen molecular bond, entering the circulatory system from intestinal epithelial cells and playing a role in lowering blood glucose. When the oral insulin formulation is administered orally, it has high bioavailability and good blood glucose lowering effect in mammals and can be used for the treatment of diabetes.
Owner:FUZHOU UNIV

Application of knock-down intestinal epithelial cell Mysm1 in increasing secretion of 5-HT by intestinal epithelial cells

The invention discloses an application of knocking down intestinal epithelial cells Mysm1 in increasing secretion of 5-HT by the intestinal epithelial cells. The invention provides application of a substance capable of inhibiting Mysm1 gene expression and / or activity in promoting intestinal tract / intestinal epithelial cells to secrete 5-hydroxytryptamine. According to the invention, the synthesis amount of the 5-HT in the intestinal tract can be manually regulated and controlled, so that the functions of the 5-HT in intestinal brain communication, intestinal tract barrier and the like are regulated and controlled; a product for promoting intestinal epithelial cells to secrete 5-hydroxytryptamine can be prepared, so that the 5-HT function is productized, and the use is convenient.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Bifidobacterium longum subsp. Longum and application thereof in improving asthma and high histamine level

ActiveCN119144530ABacteriaDigestive systemBiotechnologyStaphylococcus aureus enterotoxin
The invention discloses bifidobacterium longum subsp. Longum and application thereof in improving asthma and high histamine level, and belongs to the technical field of marine microorganisms. The invention discloses a bifidobacterium longum subsp. Longum NHNK-619, which is preserved in the China Center for Type Culture Collection on August 9, 2024, and the preservation number of the bifidobacterium longum subsp. Longum NHNK-619 is CCTCC (China Center for Type Culture Collection) NO: M20241760. The NHNK-619 has the functions of regulating asthma-related flora, agglutinating asthma-related pathogenic bacteria, reducing staphylococcus aureus enterotoxin, reducing bronchial histamine receptor activation, promoting bronchial barrier integrity, reducing airway remodeling and degrading histamine, and a thallus biofilm formed by the NHNK-619 can improve the colonization ability to intestinal epithelial cells. The compound can be used for preparing products for improving asthma and high histamine level.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Application of lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Lactobacillus plantarum-derived inorganic polyphosphate and application thereof in promoting cell proliferation

The invention relates to lactobacillus plantarum-derived inorganic polyphosphate and application thereof in promoting cell proliferation. The preparation method of the lactobacillus plantarum-derived inorganic polyphosphate comprises the following step: extracting from lactobacillus plantarum by using glass milk. According to the invention, long-chain PolyP (PolyPLp) with the chain length of about 250 phosphate residues is extracted and purified from lactobacillus plantarum by using glass milk. And the effect of promoting cell proliferation is proved. An IL-1beta-induced Caco-2 intestinal epithelial cell barrier injury model is utilized, it is found that PolyP has the function of relieving intestinal inflammation, the effect of PolyP has chain length dependence, and the action effect of PolyPLp is optimal.
Owner:FEED RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Lactobacillus reuteri for improving allergic rhinitis and nasosinusitis as well as product and application of lactobacillus reuteri

The invention relates to the technical field of microorganisms, in particular to lactobacillus reuteri for improving allergic rhinitis and nasosinusitis as well as a product and application thereof. The lactobacillus reuteri NHNK-2001 disclosed by the invention is deposited in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024800. Experiments show that the NHNK-2001 has the functions of inhibiting the growth of nasosinusitis related flora and biofilm formation, flocculating rhinitis pathogenic bacteria, promoting the growth of nasal cavity beneficial bacteria, inhibiting staphylococcus aureus subsp.aureus enterotoxin, degrading histamine, reducing histamine excitation, promoting nasal cavity epithelial cell barrier and reducing nasal cavity epithelial cell inflammation; in addition, a biological membrane formed by the NHNK-2001 thallus can increase the colonization ability to intestinal epithelial cells. The traditional Chinese medicine composition can be used for preparing products for improving allergic rhinitis and nasosinusitis.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Application of pyrrosia lingua aqueous extract in preparation of medicine for preventing and treating radioactive intestinal injury

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.
Owner:SICHUAN INST OF ATOMIC ENERGY

Pachymic acid pharmaceutical composition for preventing and treating ulcerative colitis and application thereof

The application discloses a pachymic acid medicine composition for preventing and treating ulcerative colitis and application thereof, and relates to the technical field of medical application. The composition is prepared from the following components in parts: pachymic acid 100-500 parts, carboxymethyl cellulose solution 10-100 parts, medicinal adjuvant 10-120 parts, synergistic adjuvant 10-100 parts, solvent 10-50 parts, and purified water 100-120 parts. The pachymic acid is used as a clear monomer active ingredient to prepare a medicine for preventing and treating ulcerative colitis. Compared with the existing compound, extract or multi-component combination technical scheme, the application has the characteristics of clear active ingredient, relatively clear efficacy basis, convenient quality control and subsequent development. It is clear that the ulcerative colitis can be prevented and treated by inhibiting the cGAS-STING and NF-κB signal pathways, reducing the damage of the colon epithelial cells, inhibiting the release of pro-inflammatory factors, repairing the damaged intestinal mucus barrier and intestinal epithelial barrier, regulating the apoptosis balance of intestinal cells, and enhancing the antioxidant activity of the intestinal tract. The application plays a role in preventing and treating ulcerative colitis from multiple targets such as inflammation inhibition, barrier repair and antioxidant.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE

Application of pig exosome ssc-miR-22-3p in preparation of inhibitor drug targeting MAPK14 gene

The invention discloses an application of a pig exosome ssc-miR-22-3p in preparation of an inhibitor drug of a targeted MAPK14 gene, and belongs to the field of livestock disease drugs. In order to research the effect of the pig milk exosome ssc-miR-22-3p in intestinal inflammation, LPS and Poly (I: C) are used for stimulating IPEC-J2 cells to construct an inflammation injury model, and a molecular mechanism of the pig milk exosome ssc-miR-22-3p in resisting intestinal epithelial cell injury induced by the LPS and Poly (I: C) in IPEC-J2 is planned to be further researched. And an important scientific basis is provided for research on regulation and control of intestinal inflammation reaction by the pig milk exosome miRNA.
Owner:GANSU AGRI UNIV

Embedded probiotic and prebiotic co-fermentation system with targeted delivery function for colonization and nutrient biotransformation and method of preparation thereof

A probiotic and prebiotic-embedded synbiotic system for targeted delivery and colonization of functions, comprising a probiotic core; an inner layer of protein-polysaccharide / oligosaccharide complex wrapped around the probiotic surface, which acts as both an adhesion promoter, promoting the attachment of probiotics to the intestinal epithelial cells, and as a prebiotic, promoting the growth of probiotics upon release; and an outer layer of a natural emulsifying system on the synbiotic complex, which minimizes water infiltration, thereby effectively embedding and protecting the probiotics. The present synbiotic system is suitable for production in powder form using freeze-drying technology, and is suitable as a dietary supplement or for addition to any food in dry powder form. The system has the ability to bioconvert soy isoflavones and release bioactive phenolic acids from grains to promote body health.
Owner:NANO & ADVANCED MATERIALS INST

Human milk oligosaccharide compositions and applications that inhibit Escherichia coli adhesion to intestinal epithelial cells

This invention relates to the field of human milk oligosaccharide technology, and in particular to a human milk oligosaccharide composition and its application that inhibits Escherichia coli adhesion to intestinal epithelial cells. The composition comprises 2'-fucosylated lactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), and 6'-sialic acid lactose (6'-SL) in a mass ratio of A:B:C. When 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 6'-sialic acid lactose are combined in a specific mass ratio, they exhibit superior anti-E. coli adhesion effects compared to equal amounts of breast milk or any single monomer of 2'-fucosylated lactose, lactose-N-neotetrasaccharide, or 6'-sialic acid lactose. The composition obtained by this invention possesses excellent resistance to harmful bacterial infections, and is particularly suitable for intestinal mucosal protection or repair in individuals with fragile intestinal mucosa, such as infants, the elderly, and patients with intestinal diseases. It can be used to prepare pharmaceuticals or foods for the prevention and treatment of intestinal diseases caused by Escherichia coli.
Owner:BIOSTIME GUANGZHOU HEALTH PROD

A mellea extract for treating ulcerative colitis, and its preparation method and application

The present invention provides a kind of radix schizonepetae extract for treating ulcerative colitis and its preparation method and application, and relates to the field of biomedicine technology. The preparation method of the radix schizonepetae extract of the present invention comprises: soaking radix schizonepetae in water, heating and boiling, condensing and refluxing, filtering, and collecting the filtrate, which is the radix schizonepetae extract. The radix schizonepetae extract of the present invention can reduce collagen deposition and intestinal epithelial cell apoptosis in the colon epithelium of ulcerative colitis, has the effect of downregulating the abnormally high expression of genes and proteins such as N-cadherin, IntegrinA1, Vinculin, TGF-β2, Srcin, etc. in the colon tissue of ulcerative colitis, reduces colon fibrosis and inflammatory damage, protects the barrier function of the colon epithelium, and has the effect of inhibiting the overexpression of Wnt 5A / B and β-Catenin proteins caused by DSS, and alleviates colon fibrosis, thereby achieving the effect of treating ulcerative colitis and alleviating colon fibrosis.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Lactobacillus crispatus for improving thrombosis and vascular health and its products and applications

The present invention discloses a Lactobacillus crispatus strain for improving thrombosis and vascular health and its products and applications, and relates to the technical field of microorganisms. The present invention discloses a Lactobacillus crispatus strain, which is Lactobacillus crispatus ( Lactobacillus crispatus ) NHNK‑608, which was deposited in the China Center for Type Culture Collection on March 7, 2024, and its deposit number is CCTCC NO: M 2024421. Experiments have shown that NHNK‑608 has the functions of dissolving blood clots, promoting the production of urokinase, increasing the anticoagulant factor of vascular endothelial cells, promoting the growth of vascular endothelial cells, promoting the repair of oxidative damage of vascular endothelial cells, and reducing inflammation and apoptosis of vascular endothelial cells. The bacterial biofilm increases the colonization ability of mucin and intestinal epithelial cells, and can be used to prepare products that improve blood clots and vascular health.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

A bioactive peptide with antioxidant function TDEFQLHTNVNDGTEFGGSIYQK

The present invention discloses a bioactive peptide TDEFQLHTNVNDGTEFGGSIYQK with antioxidant function, and its amino acid sequence is: Thr-Asp-Glu-Phe-Gln-Leu-His-Thr-Asn-Val-Asn-Asp-Gly-Thr-Glu-Phe-Gly-Gly-Ser-Ile-Tyr-Gln-Lys. The bioactive peptide TDEFQLHTNVNDGTEFGGSIYQK of the present invention can withstand digestion by gastrointestinal digestive enzymes, and can be completely absorbed by intestinal epithelial cells, and will not be degraded by enzymes of intestinal epithelial cells. And through cell experiments, it is verified that TDEFQLHTNVNDGTEFGGSIYQK has good antioxidant function. The bioactive peptide is of great significance for the development of drugs with antioxidant function.
Owner:DONGGUAN UNIV OF TECH

A composition for treating radiation-induced intestinal injury and use thereof

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY